Prellis Biologics Overview
At Prellis Biologics, we are driven by our vision of a world where functional human tissues can be created on demand in a laboratory setting.
Our mission is to provide organs and tissues to patients in need of a transplant or with an unmet medical need for which transplantation was previously not an option.
Our team of biologists, tissue engineers, and physicists have cracked the final engineering problem in building human organs: the rapid creation of tiny blood vessels known as microvasculature.
Microvasculature is a fundamental building block of human organs. Without microvasculature, organs are starved of oxygen and nutrients. Using our proprietary 3D laser-based printing, we can build microvasculature and additional layers of tissue with near instantaneous speeds and single-cell precision.
Because our technology allows for direct printing of structures from computer aided design (CAD) files, we are using real human vascular and cellular data to recreate complex functional organs such as kidney, liver, and lung. This approach will provide a life-saving option for over 90 million people (in the US alone) living with some form of organ failure or dysfunction.
Our primary application is the creation of transplantable human organs and tissues. Our aim is to address the organ shortage and provide human tissues to streamline the development of therapeutics.
The first human tissue Prellis Biologics is working to develop are the insulin secreting units of the pancreas, Islets of Langerhans. A renewable and safe source of Islets of Langerhans will provide the millions of people living with Type 1 Diabetes Mellitus (T1DM) an option to live free of daily insulin injections.
In addition, our company has developed a printing process to create human Lymph Node Organoids LNO-TM, capable of immune responses and generation of human antibodies, bypassing the need for antibody development in animals. In our proof-of-concept studies, our scientists created 14 novel class-switched human IgG antibodies that are reactive to the Zika Virus in less than 8 weeks.
By engineering human tissues in the laboratory for rapid therapeutics development, our technology will streamline bench-to-bedside research and efficiently address emerging diseases.